Ip, Michael S <br/><br/>
Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.  [electronic resource] 

 -  JAMA ophthalmology  03 2019 
 - 281-287 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2168-6173 
<br/><br/><label>Standard No.: </label>10.1001/jamaophthalmol.2018.6111  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--therapeutic use<br/>Bevacizumab--therapeutic use<br/>Female<br/>Humans<br/>Intravitreal Injections<br/>Macular Edema--drug therapy<br/>Male<br/>Middle Aged<br/>Receptors, Vascular Endothelial Growth Factor--therapeutic use<br/>Recombinant Fusion Proteins--therapeutic use<br/>Retinal Vein Occlusion--complications<br/>Tomography, Optical Coherence<br/>Visual Acuity